Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for TScan Therapeutics, Inc. (TCRX : NSDQ)

• Company Description    TScan Therapeutics Inc. is a biopharmaceutical company. It focused on the development of T-cell receptor engineered T cell therapies for the treatment of patients with cancer. The company's lead product pipeline consist TSC-100 and TSC-101. TScan Therapeutics Inc. is based in WALTHAM, Mass. Number of Employees: 105

• Price / Volume Information    Yesterday's Closing Price: $3.05 Daily Weekly Monthly 20 Day Moving Average: 276,280 shares Shares Outstanding: 23.77 (millions) Market Capitalization: $72.49 (millions) Beta: 52 Week High: $14.71 52 Week Low: $1.60 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 24.49% 36.31% 12 Week -27.47% -18.48% Year To Date -32.22% -17.20%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 830 WINTER STREET - WALTHAM,MA 02451 USA ph: 857-399-9500 fax: - hsavelle@tscan.com http://www.tscan.com

• General Corporate Information    Officers David Southwell - Chief Executive Officer; President and Director Brian Silver - Chief Financial Officer Stephen Biggar - Director Ittai Harel - Director Timothy Barberich - Director Peer Information TScan Therapeutics, Inc. (CORR.) TScan Therapeutics, Inc. (RSPI) TScan Therapeutics, Inc. (CGXP) TScan Therapeutics, Inc. (BGEN) TScan Therapeutics, Inc. (GTBP) TScan Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 89854M101 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/18/22 Share - Related Items Shares Outstanding: 23.77 Most Recent Split Date: (:1) Beta: Market Capitalization: $72.49 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.76 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.98 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/18/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.50 Price/Cash Flow: - Price / Sales: 6.51 EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: 49.04% vs. Previous Quarter: 5.85% ROE 03/31/22 - -54.09 12/31/21 - -86.48 09/30/21 - -779.91 ROA 03/31/22 - -32.91 12/31/21 - -29.30 09/30/21 - -32.14 Current Ratio 03/31/22 - 7.89 12/31/21 - 7.76 09/30/21 - 8.15 Quick Ratio 03/31/22 - 7.89 12/31/21 - 7.76 09/30/21 - 8.15 Operating Margin 03/31/22 - -510.72 12/31/21 - -479.49 09/30/21 - -522.54 Net Margin 03/31/22 - -510.72 12/31/21 - -479.49 09/30/21 - -522.54 Pre-Tax Margin 03/31/22 - -510.72 12/31/21 - -479.49 09/30/21 - -522.54 Book Value 03/31/22 - 6.13 12/31/21 - 6.76 09/30/21 - 7.33 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00

Powered by Zacks Investment Research ©